Trelagliptin
- Generic Name
- Trelagliptin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C18H20FN5O2
- CAS Number
- 865759-25-7
- Unique Ingredient Identifier
- Q836OWG55H
- Background
Trelagliptin is under investigation in clinical trial NCT03555591 (Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus").
- Indication
用于治疗2型糖尿病。
- Associated Conditions
- Glycemic Index
- Associated Therapies
- -
Dose Modification Requirement for Trelagliptin in Egyptian Population
- First Posted Date
- 2020-05-05
- Last Posted Date
- 2020-05-05
- Lead Sponsor
- British University In Egypt
- Target Recruit Count
- 6
- Registration Number
- NCT04374864
- Locations
- 🇪🇬
The British University in Egypt, Cairo, El Sherouk, Egypt
Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Severe Renal Impairment or End-stage Renal Disease"
- First Posted Date
- 2020-02-26
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Takeda
- Target Recruit Count
- 89
- Registration Number
- NCT04285983
- Locations
- 🇯🇵
Takeda Selected Site, Tokyo, Japan
Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus"
- First Posted Date
- 2018-06-13
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Takeda
- Target Recruit Count
- 3198
- Registration Number
- NCT03555591
- Locations
- 🇯🇵
Takeda Selected Site, Tokyo, Japan
Treatment Preference for Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Versus Daily DPP-4 Inhibitors in Participants With Type 2 Diabetes Mellitus
- First Posted Date
- 2017-07-27
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Takeda
- Target Recruit Count
- 60
- Registration Number
- NCT03231709
- Locations
- 🇯🇵
OCROM Clinic, Suita, Osaka, Japan
🇯🇵ToCROM Clinic, Shinjuku, Tokyo, Japan
Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2017-01-09
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Takeda
- Target Recruit Count
- 219
- Registration Number
- NCT03014479
- Locations
- 🇯🇵
Takeda Selected Site 1, Suita, Osaka, Japan
🇯🇵Takeda Selected Site 13, Shinagawa-ku, Tokyo, Japan
🇯🇵Takeda Selected Site 8, Shinjuku-ku, Tokyo, Japan
An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2016-05-12
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Takeda
- Target Recruit Count
- 27
- Registration Number
- NCT02771093
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath